Levetiracetam in Sodium Chloride
Brand Names: Levetiracetam in Sodium Chloride Generic
Methodology & AI Transparency ⓘ
Levetiracetam in Sodium Chloride Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Levetiracetam in Sodium Chloride Injection is indicated for adjunct therapy in adults (≥16 years of age) with the following seizure types when oral administration is temporarily not feasible: Partial-onset seizures ( 1.1 ) Myoclonic seizures in patients with juvenile myoclonic epilepsy ( 1.2 ) Primary generalized tonic-clonic seizures ( 1.3 ) 1.1 Partial-Onset Seizures Levetiracetam in Sodium Chloride Injection is indicated as adjunctive therapy in the treatment of partial-onset seizures in adults with epilepsy.
- 2 Real-world patient consensus: Tracked across 21 patient dosage logs with a 90% satisfaction benchmark (RxCUI 1193358).
- 3 Typical cash cost range: Public pharmacy ledger: $15.24 low cash benchmark vs. $37.34 chain retail average ($0.1663/unit CMS NADAC).
- 4 Top reported side effects / signs: Key post-marketing and trial adverse reactions (Levetiracetam in Sodium Chloride): dizziness (7.9%), fatigue (7.7%), somnolence (5%).
Ask our AI Specialists anything about Levetiracetam in Sodium Chloride
Levetiracetam in Sodium Chloride Mechanism, CYP450 Pathways & DailyMed Monograph
Levetiracetam in Sodium Chloride Injection is indicated for adjunct therapy in adults (≥16 years of age) with the following seizure types when oral administration is temporarily not feasible: Partial-onset seizures ( 1.1 ) Myoclonic seizures in patients with juvenile myoclonic epilepsy ( 1.2 ) Primary generalized tonic-clonic seizures ( 1.3 ) 1.1 Partial-Onset Seizures Levetiracetam in Sodium Chloride Injection is indicated as adjunctive therapy in the treatment of partial-onset seizures in adults with epilepsy.
12.1 Mechanism of Action The precise mechanism(s) by which levetiracetam exerts its antiepileptic effect is unknown. A saturable and stereoselective neuronal binding site in rat brain tissue has been described for levetiracetam. Experimental data indicate that this binding site is the synaptic vesicle protein SV2A, thought to be involved in the regulation of vesicle exocytosis.
Systemic exposure to Levetiracetam in Sodium Chloride reflects Complete (~100%) parenteral systemic delivery for Levetiracetam in Sodium Chloride (500 mg/100mL Injection) absorption kinetics and mixed metabolic conjugation and unchanged urinary excretion across levetiracetam in sodium chloride regimens, sustaining receptor engagement across a Terminal t½ estimated at 4–14 hrs depending on renal/hepatic reserve (Levetiracetam in Sodium Chloride) half-life window (rapid intravascular/parenteral onset within 15–45 minutes after levetiracetam in sodium chloride administration response profile).
Dosing protocols (500 mg/100mL Injection or 1000 mg/100mL Injection or 1500 mg/100mL Injection or 5 mg/mL Injection or 15 mg/mL Injection) balance efficacy (90.00% patient satisfaction across 21 logs) against nausea (9.4% of reports), headache (8.6% of reports), dizziness (7.9% of reports), with strict avoidance in levetiracetam in sodium chloride injection is contraindicated in patients with a hypersensitivity to levetiracetam.; reactions have included anaphylaxis and angioedema .; known hypersensitivity to levetiracetam.
Assess baseline hepatic panels and interacting prescriptions when starting Levetiracetam in Sodium Chloride (decreased central nervous system disorganized electrical activity).
Botanical enzyme modulators may alter oral first-pass exposure of Levetiracetam in Sodium Chloride; disclose all supplements.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Levetiracetam in Sodium Chloride Injection is contraindicated in patients with a hypersensitivity to levetiracetam.
- Reactions have included anaphylaxis and angioedema .
- Known hypersensitivity to levetiracetam
Logged Side-Effect Incidence (21 Reports)
Levetiracetam in Sodium Chloride Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Levetiracetam in Sodium Chloride)
Human clinical trial evidence for Levetiracetam in Sodium Chloride is indexed directly from the U.S. National Library of Medicine NCBI PubMed database. Explore recent randomized trials in the PubMed Research Pulse .
Levetiracetam in Sodium Chloride Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $0.1663/unit (~$4.99/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $37.34 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 21 Anonymous DotMD Community Micro-Logs | $15.24 / mo | View logs ↓ |
Levetiracetam in Sodium Chloride Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Levetiracetam in Sodium Chloride RxNorm Concept ID | 1193358 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.1663 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $37.34 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $15.24 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 90.00% Worth It (21 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Levetiracetam in Sodium Chloride Patient Community, Cohort Filters & Dosage Logs
Evidence synthesis for Levetiracetam in Sodium Chloride: FDA labeling (2024-04-01, NDC 55150-246), CYP/interaction screening, and public pharmacy acquisition costs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Levetiracetam in Sodium Chloride community threads and patient logs by age, biological sex, dosage, and treatment duration.